Blog

Registration is open for FDA – AACR workshop on DPD deficiency testing, the current landscape and future directions

aacr.org

Dec 27, 2024, 07:00

Registration is open for FDA – AACR workshop on DPD deficiency testing, the current landscape and future directions

“FDA Oncology and AACR are jointly holding a workshop to discuss DPD deficiency testing, the current landscape and future directions. Hope to see many of you there on January 16, 2025 – register for in-person or virtual attendance.”

Wafik El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, shared this post, adding:

“DPD deficiency testing is strongly recommended and should be obtained on all patients before they receive 5-FU or capecitabine-based chemotherapy. Available testing doesn’t catch all risks but minimizes risk of severe toxicity or death.

I do this test on all of my patients before administering these drugs. You never want to see the horrible toxicity of 5-FU even if 1:1,000 or 1:10,000. It is way overdue to have this as a guideline in Oncology.”

More posts featuring FDA Oncology and Wafik El-Deiry.

Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.

He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.